Corporate Profile
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR (Diazoxide Choline) Extended-Release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.
Latest Quarterly Earnings
Press Releases
Events
Mar 4, 2024 1:30 PM EST
Feb 14, 2024 from 11:20 AM to 11:50 AM EST
Feb 8, 2024 2:30 PM EST